Nexavar sorafenib: Completed Phase III enrollment

BAYG and ONXX completed enrollment of about 250 patients in a double-blind, international Phase III trial of sorafenib plus carboplatin and paclitaxel to treat advanced metastatic melanoma. Patients m...